@article {10783, title = {Gadolinium tissue deposition in the periodontal ligament of mice with reduced renal function exposed to Gd-based contrast agents.}, journal = {Toxicol Lett}, volume = {301}, year = {2019}, month = {2019 Feb}, pages = {157-167}, abstract = {

Gadolinium deposition in tissue is linked to nephrogenic systemic fibrosis (NSF): a rare disorder occurring in patients with severe chronic kidney disease and associated with administration of Gd-based contrast agents (GBCAs) for Magnetic Resonance Imaging (MRI). It is suggested that the GBCAs prolonged permanence in blood in these patients may result in a Gd precipitation in peripheral or central organs, where it initiates a fibrotic process. In this study we investigated new sites of retention/precipitation of Gd in a mouse model of renal disease (5/6 nephrectomy) receiving two doses (closely after each other) of a linear GBCA. Two commercial GBCAs (Omniscan{\textregistered} and Magnevist{\textregistered}) were administered at doses slightly higher than those used in clinical practice (0.7 mmol/kg body weight, each). The animals were sacrificed one month after the last administration and the explanted organs (kidney, liver, femur, dorsal skin, teeth) were analysed by X-ray fluorescence (XRF) at two synchrotron facilities. The XRF analysis with a millimetre-sized beam at the SYRMEP beamline (Elettra, Italy) produced no detectable levels of Gd in the examined tissues, with the notable exception of the incisors of the nephrectomised mice. The XRF analyses at sub-micron resolution performed at ID21 (ESRF, France) allowed to clearly localize Gd in the periodontal ligaments of teeth both from Omniscan{\textregistered} and Magnevist{\textregistered} treated nephrectomised mice. The latter results were further confirmed by laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS). The study prompts that prolonged permanence of GBCAs in blood may result in Gd retention in this particular muscular tissue, opening possibilities for diagnostic applications at this level when investigating Gd-related toxicities.

}, keywords = {Animals, Contrast Media, Disease Models, Animal, Dose-Response Relationship, Drug, Female, Gadolinium, Gadolinium DTPA, Magnetic Resonance Imaging, Mice, Nephrogenic Fibrosing Dermopathy, Periodontal Ligament, Renal Insufficiency, Tissue Distribution}, issn = {1879-3169}, doi = {10.1016/j.toxlet.2018.11.014}, author = {Delfino, Riccarda and Biasotto, Matteo and Candido, Riccardo and Altissimo, Matteo and Stebel, Marco and Salom{\`e}, Murielle and van Elteren, Johannes T and Vogel Miku{\v s}, Katarina and Zennaro, Cristina and {\v S}ala, Martin and Addobbati, Riccardo and Tromba, Giuliana and Pascolo, Lorella} } @article {10482, title = {Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients.}, journal = {BMC Nephrol}, volume = {18}, year = {2017}, month = {2017 Jul 06}, pages = {219}, abstract = {

BACKGROUND: Osteoprotegerin (OPG) is a glycoprotein that plays an important regulatory role in the skeletal, vascular, and immune system. It has been shown that OPG predicts chronic kidney disease (CKD) in diabetic patients. We hypothesized that OPG could be a risk marker of CKD development also in non-diabetic hypertensive patients.

METHODS: A case-control study was carried out to measure circulating OPG levels in 42 hypertensive patients with CKD and in 141 hypertensive patients without CKD. A potential relationship between OPG and the presence of CKD was investigated and a receiver-operating characteristic (ROC) curve was designed thereafter to identify a cut-off value of OPG that best explained the presence of CKD. Secondly, to evaluate whether OPG increase could affect the kidney, 18 C57BL/6J mice were randomized to be treated with saline or recombinant OPG every 3~weeks for 12~weeks.

RESULTS: Circulating OPG levels were significantly higher in hypertensive patients with CKD, and there was a significant inverse association between OPG and renal function, that was independent from other variables. ROC analysis showed that OPG levels had a high statistically predictive value on CKD in hypertensive patients, which was greater than that of hypertension. The OPG best cut-off value associated with CKD was 1109.19~ng/L. In the experimental study, OPG delivery significantly increased the gene expression of pro-inflammatory and pro-fibrotic mediators, as well as the glomerular nitrosylation of proteins.

CONCLUSIONS: This study shows that OPG is associated with CKD in hypertensive patients, where it might have a higher predictive value than that of hypertension for CKD development. Secondly, we found that OPG delivery significantly increased the expression of molecular pathways involved in kidney damage. Further longitudinal studies are needed not only to evaluate whether OPG predicts CKD development but also to clarify whether OPG should be considered a risk factor for CKD.

}, keywords = {Aged, Animals, Biomarkers, Case-Control Studies, Female, Follow-Up Studies, Humans, Hypertension, Male, Mice, Mice, Inbred C57BL, Middle Aged, Osteoprotegerin, Random Allocation, Renal Insufficiency, Chronic}, issn = {1471-2369}, doi = {10.1186/s12882-017-0625-3}, author = {Bernardi, Stella and Toffoli, Barbara and Bossi, Fleur and Candido, Riccardo and Stenner, Elisabetta and Carretta, Renzo and Barbone, Fabio and Fabris, Bruno} } @article {8330, title = {The incidence rate and prevalence of pediatric type 1 diabetes mellitus (age 0-18) in the Italian region Friuli Venezia Giulia: population-based estimates through the analysis of health administrative databases.}, journal = {Acta Diabetol}, volume = {53}, year = {2016}, month = {2016 Aug}, pages = {629-35}, abstract = {

AIMS: The main objective of this study was to estimate the incidence rate and prevalence of pediatric type 1 diabetes mellitus (T1DM; population 0-18~years of age) in the northeastern Italian region Friuli Venezia Giulia and to characterize the subjects affected by the disease.

METHODS: This was a retrospective population-based study conducted through the individual-level linkage of several health administrative databases of the Friuli Venezia Giulia region. The incidence rate and prevalence were calculated in the population 0-18~years of age. Using the Mid-p exact method, 95~\% confidence intervals for rates were calculated.

RESULTS: The incidence rate of pediatric T1DM in the years 2010-2013 was 15.8 new cases/100,000 person-years, peaking in the age class 10-14~years. The rate has increased substantially as compared with the previous regional estimate that dated back to 1993. We observed a seasonal pattern both in the date of birth of the incident cases and in the date of onset of the disease. In the region in 2013, there were 294 prevalent cases (15.1/10,000 inhabitants). Most of them had at least one glycated hemoglobin test in the year. More than 15~\% had co-existing autoimmune comorbidities.

CONCLUSIONS: The incidence rate of pediatric T1DM in Friuli Venezia Giulia has increased in the last years, and the disease is a relevant public health issue in the region.

}, issn = {1432-5233}, doi = {10.1007/s00592-016-0854-0}, author = {Valent, Francesca and Candido, Riccardo and Faleschini, Elena and Tonutti, Laura and Tortul, Carla and Zanatta, Manuela and Zanette, Giorgio and Zanier, Loris} } @article {3579, title = {Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes.}, journal = {Mol Cell Endocrinol}, volume = {394}, year = {2014}, month = {2014 Aug 25}, pages = {13-20}, abstract = {

BACKGROUND: Inflammation is believed to link obesity to insulin resistance, as in the setting of metabolic syndrome (MetS). Osteoprotegerin (OPG) is a soluble protein that seems to exert proatherogenic and prodiabetogenic effects. This study aims at determining OPG levels in MetS and whether OPG might contribute to MetS development and progression.

METHODOLOGY/PRINCIPAL FINDINGS: Circulating OPG was measured in 46 patients with MetS and 63 controls, and was found significantly elevated in those with MetS. In addition, circulating and tissue OPG was significantly increased in high-fat diet (HFD) fed C57BL6 mice, which is one of the animal models for the study of MetS. To evaluate the consequences of OPG elevation, we delivered this protein to C57BL6 mice, finding that it promoted systemic and adipose tissue proinflammatory changes in association with metabolic abnormalities.

CONCLUSIONS/SIGNIFICANCE: These data suggest that OPG may trigger adipose tissue proinflammatory changes in MetS/HFD-induced obesity.

}, keywords = {Adipose Tissue, Adult, Animals, Blood Glucose, Body Mass Index, C-Reactive Protein, Case-Control Studies, Cholesterol, HDL, Cholesterol, LDL, Diet, High-Fat, Female, Humans, Inflammation, Insulin, Insulin Resistance, Male, Metabolic Syndrome X, Mice, Mice, Inbred C57BL, Middle Aged, Obesity, Osteoprotegerin, Triglycerides}, issn = {1872-8057}, doi = {10.1016/j.mce.2014.06.004}, author = {Bernardi, Stella and Fabris, Bruno and Thomas, Merlin and Toffoli, Barbara and Tikellis, Christos and Candido, Riccardo and Catena, Cristiana and Mulatero, Paolo and Barbone, Fabio and Radillo, Oriano and Zauli, Giorgio and Secchiero, Paola} } @article {1957, title = {Patients affected by metabolic syndrome show decreased levels of circulating platelet derived growth factor (PDGF)-BB.}, journal = {Clin Nutr}, volume = {32}, year = {2013}, month = {2013 Apr}, pages = {259-64}, abstract = {

BACKGROUND \& AIMS: The development and/or progression of metabolic syndrome (MetS) in overweight and obese individuals have been associated to low-grade inflammation, but few studies have simultaneously analyzed the circulating levels of several cytokines.

METHODS: In this pilot study, a group of 27 cytokines and growth factors was analyzed in the serum of obese patients (n=40) diagnosed for MetS in comparison with sex- and age-matched control subjects without MetS (n=53) by using a multiplex immunoassay. Release of cytokines was measured in culture supernatants of human primary endothelial cells, THP-1 macrophagic cells and HuH-7 hepatoma cells upon exposure to a high fat mixture.

RESULTS: While the majority of cytokines did not show significant differences between the investigated groups, the circulating levels of CXCL10/IP-10 and IL-6 were higher in the MetS group versus overweight control group. In contrast, PDGF-BB serum levels were significantly decreased in MetS patients. The in~vitro addition of a high fat mixture increased the release of IL-6 and/or CXCL10/IP-10 in the culture supernatant of human primary endothelial cells and THP-1 macrophagic cells, while the same mixture significantly decreased the release of PDGF-BB by human THP-1 macrophagic and HuH-7 hepatoma cells.

CONCLUSIONS: The current demonstration that MetS is associated with decrease of the pro-fibrotic PDGF cytokine is a completely novel finding, which adds complexity to the interplay between inflammation and fibrosis in patients affected by MetS.

}, keywords = {Adolescent, Adult, Aged, Case-Control Studies, Cell Line, Tumor, Chemokine CXCL10, Endothelial Cells, Female, Humans, Interleukin-6, Linear Models, Male, Metabolic Syndrome X, Middle Aged, Obesity, Pilot Projects, Proto-Oncogene Proteins c-sis, RNA, Messenger, Young Adult}, issn = {1532-1983}, doi = {10.1016/j.clnu.2012.07.003}, author = {Tisato, Veronica and Toffoli, Barbara and Monasta, Lorenzo and Bernardi, Stella and Candido, Riccardo and Zauli, Giorgio and Secchiero, Paola} } @article {1911, title = {TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation.}, journal = {Clin Sci (Lond)}, volume = {123}, year = {2012}, month = {2012 Nov}, pages = {547-55}, abstract = {

TRAIL [TNF (tumour necrosis factor)-related apoptosis-inducing ligand] has recently been shown to ameliorate the natural history of DM (diabetes mellitus). It has not been determined yet whether systemic TRAIL delivery would prevent the metabolic abnormalities due to an HFD [HF (high-fat) diet]. For this purpose, 27 male C57bl6 mice aged 8 weeks were randomly fed on a standard diet, HFD or HFD+TRAIL for 12 weeks. TRAIL was delivered weekly by intraperitoneal injection. Body composition was evaluated; indirect calorimetry studies, GTT (glucose tolerance test) and ITT (insulin tolerance test) were performed. Pro-inflammatory cytokines, together with adipose tissue gene expression and apoptosis, were measured. TRAIL treatment reduced significantly the increased adiposity associated with an HFD. Moreover, it reduced significantly hyperglycaemia and hyperinsulinaemia during a GTT and it improved significantly the peripheral response to insulin. TRAIL reversed the changes in substrate utilization induced by the HFD and ameliorated skeletal muscle non-esterified fatty acids oxidation rate. This was associated with a significant reduction of pro-inflammatory cytokines together with a modulation of adipose tissue gene expression and apoptosis. These findings shed light on the possible anti-adipogenic and anti-inflammatory effects of TRAIL and open new therapeutic possibilities against obesity, systemic inflammation and T2DM (Type 2 DM).

}, keywords = {Adiposity, Animals, Apoptosis, Calorimetry, Cytokines, Dietary Fats, Energy Intake, Glucose Tolerance Test, Hyperglycemia, Hyperinsulinism, Inflammation, Inflammation Mediators, Male, Mice, Mice, Inbred C57BL, Oxidation-Reduction, Palmitic Acid, Real-Time Polymerase Chain Reaction, TNF-Related Apoptosis-Inducing Ligand}, issn = {1470-8736}, doi = {10.1042/CS20120176}, author = {Bernardi, Stella and Zauli, Giorgio and Tikellis, Christos and Candido, Riccardo and Fabris, Bruno and Secchiero, Paola and Cooper, Mark E and Thomas, Merlin C} } @article {1709, title = {TRAIL shows potential cardioprotective activity.}, journal = {Invest New Drugs}, volume = {30}, year = {2012}, month = {2012 Jun}, pages = {1257-60}, abstract = {

Recent clinical trials carried out in patients with advanced cancer have shown that recombinant TRAIL administration is usually safe and well tolerated when used either alone or in association with chemotherapeutic drugs. Notably, anticancer chemotherapy can be associated to cardiomiopathy. We have here demonstrated that TRAIL (administrated as either recombinant soluble TRAIL or as AAV-TRAIL expression viral vector) reduced the development of cardiomyopathy in the ApoE(-/-) diabetic mouse model. These data suggest, for the first time, that therapeutically administration of TRAIL might have a cardioprotective effect.

}, keywords = {Animals, Apolipoproteins E, Apoptosis, Cardiotonic Agents, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 1, Diabetic Cardiomyopathies, Fibrosis, Male, Mice, Mice, Knockout, Recombinant Proteins, TNF-Related Apoptosis-Inducing Ligand}, issn = {1573-0646}, doi = {10.1007/s10637-010-9627-8}, author = {Toffoli, Barbara and Bernardi, Stella and Candido, Riccardo and Zacchigna, Serena and Fabris, Bruno and Secchiero, Paola} } @article {1710, title = {Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets.}, journal = {Mol Cell Endocrinol}, volume = {331}, year = {2011}, month = {2011 Jan 1}, pages = {136-42}, abstract = {

Although serum osteoprotegerin (OPG) is significantly increased in diabetic subjects, its potential role in beta cell dysfunction has not been investigated. This study aimed to assess the effect of full-length OPG administered in vivo in mice on pancreatic islet structure and function and its interaction with the renin-angiotensin system (RAS). OPG-treated mice showed increased islet monocyte/macrophage infiltration, fibrosis and apoptosis with reduction of islet function. The remodeling of islet architecture was associated with increased pancreatic expression of components of the RAS, growth factor genes (transforming growth factor β and connective tissue growth factor) and inflammatory molecules (monocyte chemotactic protein-1 and vascular adhesion molecule type 1). Prevention of these changes with improvement of insulin secretion was observed in ramipril treated animals. Our data suggest that OPG might play an important role in promoting beta cell dysfunction and that the upregulation of the local RAS represents one possible mechanism responsible for the OPG-induced beta cell dysfunction.

}, keywords = {Animals, Apoptosis, Blood Glucose, Blood Pressure, Body Weight, Cell Lineage, Cell Movement, Chemokine CCL2, Connective Tissue Growth Factor, Fibrosis, Gene Expression Regulation, Humans, Insulin, Islets of Langerhans, Macrophages, Mice, Monocytes, Organ Size, Osteoprotegerin, Peptidyl-Dipeptidase A, Receptor, Angiotensin, Type 1, Systole, Transforming Growth Factor beta, Vascular Cell Adhesion Molecule-1}, issn = {1872-8057}, doi = {10.1016/j.mce.2010.08.019}, author = {Toffoli, Barbara and Bernardi, Stella and Candido, Riccardo and Sabato, Nicoletta and Carretta, Renzo and Corallini, Federica and Secchiero, Paola and Zauli, Giorgio and Fabris, Bruno} }